Skip to main content
. 2018 Feb 12;23(3):458–465. doi: 10.1007/s10147-018-1240-4

Table 3.

Treatment toxicity

Grade 1 2 3 4
N = 65 n (%) n (%) n (%) n (%)
Neutropenia 19 (29.2) 20 (30.7) 12 (18.4) 4 (6.1)
Thrombocytopenia 19 (29.2) 10 (15.3) 3 (4.6) 0
Anaemia 27 (41.5) 15 (23.0) 1 (1.5) 0
Vomiting 7 (10.7) 4 (6.1) 1 (1.5) 0
Fever 1 (1.5) 2 (3.0) 0 0
Fatigue 9 (13.8) 6 (9.2) 1 (1.5) 0
Alopecia 10 (15.3) 6 (9.2) 0 0
Hypoalbuminaemia 13 (20.0) 3 (4.6) 0 0
ALTa 3 (4.6) 0 0 0
Radiation dermatitis 8 (12.3) 8 (12.3) 1 (1.5) 0
Oesophagitis 19 (29.2) 19 (29.2) 3 (4.6) 0
Hypocalcaemia 8 (12.3) 1 (1.5) 0 0
Hypomagnesaemia 2 (3.0) 1 (1.5) 0 0
Hyponatraemia 8 (12.3) 0 0 0
Hypophosphataemia 4 (6.1) 0 1 (1.5) 0
Constipation 2 (3.0) 6 (9.2) 0 0
Diarrhoea 1 (1.5) 2 (3.0) 0 0
Peripheral sensory neuropathy 2 (3.0) 12 (18.4) 0 0
Pneumonitis 5 (7.6) 7 (10.7) 1 (1.5) 0
Hypopotassaemia 3 (4.6) 0 0 0
Hoarseness 7 (10.7) 2 (3.0) 0 0
Ventricular arrhythmia 3 (4.6) 0 0 0
Pericardial effusion 4 (6.1) 0 0 0

Toxicity was graded according to the National Cancer Institute Common Toxicity Criteria, version 4.0

aAlanine aminotransferase increased

HHS Vulnerability Disclosure